Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyChloral hydrate
Identification
- Name
- Chloral hydrate
- Accession Number
- DB01563
- Type
- Small Molecule
- Groups
- Approved, Illicit, Investigational, Vet approved
- Description
A hypnotic and sedative used in the treatment of insomnia. The safety margin is too narrow for chloral hydrate to be used as a general anesthetic in humans, but it is commonly used for that purpose in animal experiments. It is no longer considered useful as an anti-anxiety medication.
- Structure
Structure for DB01563 (Chloral hydrate)
- Synonyms
- 1,1,1-trichloro-2,2-dihydroxyethane
- 1,1,1-trichloro-2,2-ethanediol
- 2,2,2-trichloro-1,1-ethanediol
- chloral monohydrate
- Chloralhydrat
- Trichloracetaldehyd-hydrat
- trichloroacetaldehyde hydrate
- External IDs
- NSC-3210
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Chloral Hydrate Capsules 500mg Capsule 500 mg Oral D.C. Labs Limited 1968-12-31 2003-07-11 Canada 
Chloral Hydrate Syrup Odan Syrup 100 mg Oral Odan Laboratories Ltd 2003-08-06 Not applicable Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Apo-chloral Hydrate Syrup Syrup 100 mg Oral Apotex Corporation Not applicable Not applicable Canada Novo-chlorhydrate Cap 500mg Capsule 500 mg Oral Novopharm Limited 1967-12-31 2005-08-10 Canada PMS-chloral Hydrate Capsules 500mg Capsule 500 mg Oral Pharmascience Inc 1996-10-10 Not applicable Canada PMS-chloral Hydrate Syrup 100mg/ml Syrup 100 mg Oral Pharmascience Inc 1990-12-31 Not applicable Canada - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Analgesic Balm Chloral hydrate (1 g) + Menthol (10 g) + Methyl salicylate (15 g) Ointment Topical D.C. Labs Limited 1966-12-31 2003-07-11 Canada Calmitol Itching Relief Ont Chloral hydrate (.496 %) + Camphor (.62 %) + Hyoscyamine (.0001 %) + Menthol (.58 %) + Zinc oxide (12.5 %) Ointment Topical Pfizer Canada Inc., Consumer Healthcare Division 1964-12-31 1996-09-09 Canada - International/Other Brands
- Aquachloral Supprettes (Amerifit Pharma) / Somnote (Breckenridge)
- Categories
- UNII
- 418M5916WG
- CAS number
- 302-17-0
- Weight
- Average: 165.403
Monoisotopic: 163.919862461 - Chemical Formula
- C2H3Cl3O2
- InChI Key
- RNFNDJAIBTYOQL-UHFFFAOYSA-N
- InChI
- InChI=1S/C2H3Cl3O2/c3-2(4,5)1(6)7/h1,6-7H
- IUPAC Name
- 2,2,2-trichloroethane-1,1-diol
- SMILES
- OC(O)C(Cl)(Cl)Cl
Pharmacology
- Indication
Mainly used as a hyponotic in the treatment of insomnia; however, it is only effective as a hypnotic for short-term use. May be used as a routine sedative preoperatively to decrease anxiety and cause sedation and/or sleep with respiration depression or cough reflex.
- Structured Indications
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
Rapidly absorbed in the GI tract following oral or rectal administration. Chloral hydrate and its active metabolite, trichloroethanol, have been detected in CSF, umbilical cord blood, fetal blood, and amniotic fluid.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
Metabolized by the liver and erythrocytes to form trichloroethanol, an active metabolite. This reaction is catalyzed by alcohol dehydrogenase and other enzymes. Oxidation of chloral hydrate and trichloroethanol to trichloroacetic acid in the liver and kidneys also occurs to a lesser extent. Trichloroethanol also undergoes glucuronidation to produce an inactive metabolism.
- Route of elimination
Trichloroethanol, trichloroethanol glucuronide, and trichloroacetic acid are excreted in the urine. Some trichloroethanol glucuronide may be secreted into bile and excreted in the feces.
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 7-Nitroindazole The risk or severity of adverse effects can be increased when Chloral hydrate is combined with 7-Nitroindazole. Experimental Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Chloral hydrate. Approved, Investigational Acepromazine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Acepromazine. Approved, Vet Approved Aceprometazine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Aceprometazine. Approved Adipiplon The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Adipiplon. Investigational Agomelatine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Agomelatine. Approved, Investigational Alaproclate The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Alaproclate. Experimental Alfaxalone The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Alfaxalone. Vet Approved Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Chloral hydrate. Approved, Illicit Allopregnanolone The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Allopregnanolone. Investigational Alphacetylmethadol The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Chloral hydrate. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Alphaprodine. Illicit Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Chloral hydrate. Approved, Illicit, Investigational Amisulpride The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Amisulpride. Approved, Investigational Amitriptyline The risk or severity of adverse effects can be increased when Amitriptyline is combined with Chloral hydrate. Approved Amobarbital The risk or severity of adverse effects can be increased when Amobarbital is combined with Chloral hydrate. Approved, Illicit Amoxapine The risk or severity of adverse effects can be increased when Amoxapine is combined with Chloral hydrate. Approved Amperozide The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Amperozide. Experimental Aripiprazole The risk or severity of adverse effects can be increased when Aripiprazole is combined with Chloral hydrate. Approved, Investigational Articaine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Articaine. Approved Asenapine The risk or severity of adverse effects can be increased when Asenapine is combined with Chloral hydrate. Approved Azaperone The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Azaperone. Investigational, Vet Approved Azelastine Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Approved Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Chloral hydrate. Approved Barbital The risk or severity of adverse effects can be increased when Barbital is combined with Chloral hydrate. Illicit Benperidol The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Benperidol. Approved, Investigational Benzocaine The risk or severity of adverse effects can be increased when Benzocaine is combined with Chloral hydrate. Approved, Investigational Benzyl alcohol The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Benzyl alcohol. Approved Brexpiprazole The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Chloral hydrate. Approved, Investigational Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate. Approved Bromazepam The risk or severity of adverse effects can be increased when Bromazepam is combined with Chloral hydrate. Approved, Illicit, Investigational Bromisoval The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Bromisoval. Experimental Bromperidol The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Bromperidol. Approved, Investigational Brompheniramine The risk or severity of adverse effects can be increased when Brompheniramine is combined with Chloral hydrate. Approved Brotizolam The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Brotizolam. Approved, Investigational, Withdrawn Bupivacaine The risk or severity of adverse effects can be increased when Bupivacaine is combined with Chloral hydrate. Approved, Investigational Buprenorphine Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Buspirone The risk or severity of adverse effects can be increased when Buspirone is combined with Chloral hydrate. Approved, Investigational Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Chloral hydrate. Approved, Illicit Butacaine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Butacaine. Vet Approved Butalbital The risk or severity of adverse effects can be increased when Butalbital is combined with Chloral hydrate. Approved, Illicit Butamben The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Butamben. Approved, Withdrawn Butethal The risk or severity of adverse effects can be increased when Butethal is combined with Chloral hydrate. Approved, Illicit Butorphanol The risk or severity of adverse effects can be increased when Butorphanol is combined with Chloral hydrate. Approved, Illicit, Vet Approved Canertinib The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Canertinib. Investigational Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Chloral hydrate. Approved, Investigational Carbinoxamine The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Chloral hydrate. Approved Carfentanil The risk or severity of adverse effects can be increased when Carfentanil is combined with Chloral hydrate. Illicit, Investigational, Vet Approved Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Chloral hydrate. Approved Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with Chloral hydrate. Approved Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Chloral hydrate. Approved, Illicit, Investigational Chlormezanone The risk or severity of adverse effects can be increased when Chlormezanone is combined with Chloral hydrate. Approved, Investigational, Withdrawn Chloroprocaine The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Chloral hydrate. Approved Chlorphenamine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Chloral hydrate. Approved Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Chloral hydrate. Approved, Investigational, Vet Approved Chlorprothixene The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Chloral hydrate. Approved, Investigational, Withdrawn Chlorzoxazone The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Chloral hydrate. Approved Cinchocaine The risk or severity of adverse effects can be increased when Cinchocaine is combined with Chloral hydrate. Approved, Vet Approved Citalopram The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Citalopram. Approved Clemastine The risk or severity of adverse effects can be increased when Clemastine is combined with Chloral hydrate. Approved, Investigational Clidinium The risk or severity of adverse effects can be increased when Clidinium is combined with Chloral hydrate. Approved Clobazam The risk or severity of adverse effects can be increased when Clobazam is combined with Chloral hydrate. Approved, Illicit clomethiazole The risk or severity of adverse effects can be increased when Chloral hydrate is combined with clomethiazole. Investigational Clomipramine The risk or severity of adverse effects can be increased when Clomipramine is combined with Chloral hydrate. Approved, Investigational, Vet Approved Clonazepam The risk or severity of adverse effects can be increased when Clonazepam is combined with Chloral hydrate. Approved, Illicit Clonidine The risk or severity of adverse effects can be increased when Clonidine is combined with Chloral hydrate. Approved Clopenthixol The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Clopenthixol. Experimental Clorazepate The risk or severity of adverse effects can be increased when Clorazepate is combined with Chloral hydrate. Approved, Illicit Clorindione The serum concentration of Clorindione can be increased when it is combined with Chloral hydrate. Experimental Clothiapine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Clothiapine. Experimental Clozapine The risk or severity of adverse effects can be increased when Clozapine is combined with Chloral hydrate. Approved Cocaine The risk or severity of adverse effects can be increased when Cocaine is combined with Chloral hydrate. Approved, Illicit Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Chloral hydrate. Approved, Illicit Cyclizine The risk or severity of adverse effects can be increased when Cyclizine is combined with Chloral hydrate. Approved Cyclobenzaprine The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chloral hydrate. Approved Cyclopropane The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Cyclopropane. Experimental Cyproheptadine The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Chloral hydrate. Approved Dantrolene The risk or severity of adverse effects can be increased when Dantrolene is combined with Chloral hydrate. Approved, Investigational Dapiprazole The risk or severity of adverse effects can be increased when Dapiprazole is combined with Chloral hydrate. Approved Dapoxetine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Dapoxetine. Investigational Deramciclane The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Deramciclane. Investigational Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Chloral hydrate. Approved Desipramine The risk or severity of adverse effects can be increased when Desipramine is combined with Chloral hydrate. Approved, Investigational Desloratadine The risk or severity of adverse effects can be increased when Desloratadine is combined with Chloral hydrate. Approved, Investigational Desvenlafaxine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Desvenlafaxine. Approved, Investigational Detomidine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Detomidine. Vet Approved Deutetrabenazine The risk or severity of sedation and somnolence can be increased when Chloral hydrate is combined with Deutetrabenazine. Approved, Investigational Dexbrompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Chloral hydrate. Approved Dexmedetomidine The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Chloral hydrate. Approved, Vet Approved Dextromoramide The risk or severity of adverse effects can be increased when Dextromoramide is combined with Chloral hydrate. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chloral hydrate. Approved, Illicit, Investigational, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Dezocine is combined with Chloral hydrate. Approved, Investigational Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Chloral hydrate. Approved, Illicit, Investigational, Vet Approved Dicoumarol The serum concentration of Dicoumarol can be increased when it is combined with Chloral hydrate. Approved Diethyl ether The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Diethyl ether. Experimental Difenoxin The risk or severity of adverse effects can be increased when Difenoxin is combined with Chloral hydrate. Approved, Illicit Dihydrocodeine The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chloral hydrate. Approved, Illicit Dihydroetorphine The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Chloral hydrate. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Dihydromorphine. Experimental, Illicit Dimenhydrinate The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Chloral hydrate. Approved Diphenadione The serum concentration of Diphenadione can be increased when it is combined with Chloral hydrate. Experimental Diphenhydramine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Chloral hydrate. Approved, Investigational Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chloral hydrate. Approved, Illicit Dixyrazine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Dixyrazine. Experimental Doramectin The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Doramectin. Vet Approved Doxepin The risk or severity of adverse effects can be increased when Doxepin is combined with Chloral hydrate. Approved, Investigational Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate. Approved, Vet Approved DPDPE The risk or severity of adverse effects can be increased when Chloral hydrate is combined with DPDPE. Experimental Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate. Approved, Illicit Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate. Approved, Vet Approved Drotebanol The risk or severity of adverse effects can be increased when Drotebanol is combined with Chloral hydrate. Experimental, Illicit Duloxetine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Duloxetine. Approved Dyclonine The risk or severity of adverse effects can be increased when Dyclonine is combined with Chloral hydrate. Approved Ecgonine The risk or severity of adverse effects can be increased when Ecgonine is combined with Chloral hydrate. Experimental, Illicit Ecopipam The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ecopipam. Investigational Efavirenz The risk or severity of adverse effects can be increased when Efavirenz is combined with Chloral hydrate. Approved, Investigational Eltanolone The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Eltanolone. Investigational Enflurane The risk or severity of adverse effects can be increased when Enflurane is combined with Chloral hydrate. Approved, Investigational, Vet Approved Entacapone The risk or severity of adverse effects can be increased when Entacapone is combined with Chloral hydrate. Approved, Investigational Escitalopram The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Escitalopram. Approved, Investigational Estazolam The risk or severity of adverse effects can be increased when Estazolam is combined with Chloral hydrate. Approved, Illicit Eszopiclone The risk or severity of adverse effects can be increased when Eszopiclone is combined with Chloral hydrate. Approved, Investigational Ethanol Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethchlorvynol The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chloral hydrate. Approved, Illicit, Withdrawn Ethosuximide The risk or severity of adverse effects can be increased when Ethosuximide is combined with Chloral hydrate. Approved Ethotoin The risk or severity of adverse effects can be increased when Ethotoin is combined with Chloral hydrate. Approved Ethyl biscoumacetate The serum concentration of Ethyl biscoumacetate can be increased when it is combined with Chloral hydrate. Withdrawn Ethyl carbamate The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ethyl carbamate. Withdrawn Ethyl chloride The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ethyl chloride. Approved, Experimental, Investigational Ethyl loflazepate The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Chloral hydrate. Approved, Illicit Ethylmorphine The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Chloral hydrate. Approved, Illicit Etidocaine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Etidocaine. Approved Etifoxine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Etifoxine. Investigational, Withdrawn Etizolam The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Etizolam. Approved Etomidate The risk or severity of adverse effects can be increased when Etomidate is combined with Chloral hydrate. Approved Etoperidone The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Etoperidone. Withdrawn Etorphine The risk or severity of adverse effects can be increased when Etorphine is combined with Chloral hydrate. Illicit, Vet Approved Ezogabine The risk or severity of adverse effects can be increased when Ezogabine is combined with Chloral hydrate. Approved, Investigational Felbamate The risk or severity of adverse effects can be increased when Felbamate is combined with Chloral hydrate. Approved Fencamfamine The risk or severity of adverse effects can be increased when Fencamfamine is combined with Chloral hydrate. Approved, Illicit, Withdrawn Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Chloral hydrate. Approved, Illicit, Investigational, Vet Approved Fexofenadine The risk or severity of adverse effects can be increased when Fexofenadine is combined with Chloral hydrate. Approved, Investigational Flibanserin The risk or severity of adverse effects can be increased when Flibanserin is combined with Chloral hydrate. Approved, Investigational Fluanisone The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Fluanisone. Experimental Fludiazepam The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Fludiazepam. Approved, Illicit Fluindione The serum concentration of Fluindione can be increased when it is combined with Chloral hydrate. Approved, Investigational Flunarizine The risk or severity of adverse effects can be increased when Flunarizine is combined with Chloral hydrate. Approved Flunitrazepam The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Chloral hydrate. Approved, Illicit Fluoxetine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Fluoxetine. Approved, Vet Approved Flupentixol The risk or severity of adverse effects can be increased when Flupentixol is combined with Chloral hydrate. Approved, Investigational, Withdrawn Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Chloral hydrate. Approved Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Chloral hydrate. Approved, Illicit, Investigational Fluspirilene The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Fluspirilene. Approved, Investigational Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Chloral hydrate. Approved Fluvoxamine The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Chloral hydrate. Approved, Investigational Fosphenytoin The risk or severity of adverse effects can be increased when Fosphenytoin is combined with Chloral hydrate. Approved, Investigational Fospropofol The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Fospropofol. Approved, Illicit, Investigational Furosemide The risk or severity of adverse effects can be increased when Furosemide is combined with Chloral hydrate. Approved, Vet Approved Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Chloral hydrate. Approved, Investigational Gabapentin Enacarbil The risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Chloral hydrate. Approved, Investigational Gamma Hydroxybutyric Acid The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Chloral hydrate. Approved, Illicit, Investigational Gepirone The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Gepirone. Investigational Glutethimide The risk or severity of adverse effects can be increased when Glutethimide is combined with Chloral hydrate. Approved, Illicit Guanfacine The risk or severity of adverse effects can be increased when Guanfacine is combined with Chloral hydrate. Approved, Investigational Halazepam The risk or severity of adverse effects can be increased when Halazepam is combined with Chloral hydrate. Approved, Illicit, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Haloperidol is combined with Chloral hydrate. Approved Halothane The risk or severity of adverse effects can be increased when Halothane is combined with Chloral hydrate. Approved, Vet Approved Heroin The risk or severity of adverse effects can be increased when Heroin is combined with Chloral hydrate. Approved, Illicit, Investigational Hexobarbital The risk or severity of adverse effects can be increased when Hexobarbital is combined with Chloral hydrate. Approved Hydrocodone Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chloral hydrate. Approved, Illicit Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate. Approved Iloperidone The risk or severity of adverse effects can be increased when Iloperidone is combined with Chloral hydrate. Approved Imipramine The risk or severity of adverse effects can be increased when Imipramine is combined with Chloral hydrate. Approved Indalpine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Indalpine. Investigational, Withdrawn Indiplon The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Indiplon. Investigational Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Chloral hydrate. Approved, Vet Approved Ketamine The risk or severity of adverse effects can be increased when Ketamine is combined with Chloral hydrate. Approved, Vet Approved Ketazolam The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ketazolam. Approved Ketobemidone The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ketobemidone. Approved, Investigational Lamotrigine The risk or severity of adverse effects can be increased when Lamotrigine is combined with Chloral hydrate. Approved, Investigational Levetiracetam The risk or severity of adverse effects can be increased when Levetiracetam is combined with Chloral hydrate. Approved, Investigational Levobupivacaine The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Chloral hydrate. Approved, Investigational Levocabastine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Levocabastine. Approved, Investigational Levocetirizine The risk or severity of adverse effects can be increased when Levocetirizine is combined with Chloral hydrate. Approved Levodopa The risk or severity of adverse effects can be increased when Levodopa is combined with Chloral hydrate. Approved Levomethadyl Acetate The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Chloral hydrate. Approved, Investigational Levomilnacipran The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Levomilnacipran. Approved, Investigational Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Chloral hydrate. Approved Lidocaine The risk or severity of adverse effects can be increased when Lidocaine is combined with Chloral hydrate. Approved, Vet Approved Lithium The risk or severity of adverse effects can be increased when Lithium is combined with Chloral hydrate. Approved Lofentanil The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Lofentanil. Illicit Loprazolam The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Loprazolam. Experimental Loratadine The risk or severity of adverse effects can be increased when Loratadine is combined with Chloral hydrate. Approved, Investigational Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Chloral hydrate. Approved Lormetazepam The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Lormetazepam. Approved Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Chloral hydrate. Approved Lurasidone The risk or severity of adverse effects can be increased when Lurasidone is combined with Chloral hydrate. Approved, Investigational Magnesium sulfate The therapeutic efficacy of Chloral hydrate can be increased when used in combination with Magnesium sulfate. Approved, Investigational, Vet Approved Maprotiline The risk or severity of adverse effects can be increased when Maprotiline is combined with Chloral hydrate. Approved, Investigational Mebicar The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Mebicar. Experimental Meclizine The risk or severity of adverse effects can be increased when Meclizine is combined with Chloral hydrate. Approved Medazepam The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Medazepam. Experimental Medetomidine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Medetomidine. Vet Approved Melatonin The risk or severity of adverse effects can be increased when Melatonin is combined with Chloral hydrate. Approved, Nutraceutical, Vet Approved Melperone The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Melperone. Approved, Investigational Mepivacaine The risk or severity of adverse effects can be increased when Mepivacaine is combined with Chloral hydrate. Approved, Vet Approved Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Chloral hydrate. Approved, Illicit Meptazinol The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Meptazinol. Experimental Mesoridazine The risk or severity of adverse effects can be increased when Mesoridazine is combined with Chloral hydrate. Approved, Investigational Metaxalone The risk or severity of adverse effects can be increased when Metaxalone is combined with Chloral hydrate. Approved Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Chloral hydrate. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Chloral hydrate. Approved, Illicit Methapyrilene The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Methapyrilene. Withdrawn Methaqualone The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Methaqualone. Illicit, Withdrawn Methocarbamol The risk or severity of adverse effects can be increased when Methocarbamol is combined with Chloral hydrate. Approved, Vet Approved Methohexital The risk or severity of adverse effects can be increased when Methohexital is combined with Chloral hydrate. Approved Methotrimeprazine Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. Approved, Investigational Methoxyflurane The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Chloral hydrate. Approved, Investigational, Vet Approved Methsuximide The risk or severity of adverse effects can be increased when Methsuximide is combined with Chloral hydrate. Approved Methylecgonine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Methylecgonine. Experimental Methylphenobarbital The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Chloral hydrate. Approved Metyrosine Chloral hydrate may increase the sedative activities of Metyrosine. Approved Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Chloral hydrate. Approved, Illicit Milnacipran The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Milnacipran. Approved, Investigational Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate. Approved, Investigational Mirtazapine Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. Approved Molindone The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Molindone. Approved Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Chloral hydrate. Approved, Investigational Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate. Approved, Investigational Nalbuphine The risk or severity of adverse effects can be increased when Nalbuphine is combined with Chloral hydrate. Approved Nefazodone The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Nefazodone. Approved, Withdrawn Nitrazepam The risk or severity of adverse effects can be increased when Nitrazepam is combined with Chloral hydrate. Approved Nitrous oxide The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Chloral hydrate. Approved, Vet Approved Norflurane The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Norflurane. Approved, Investigational Normethadone The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Normethadone. Approved, Illicit Nortriptyline The risk or severity of adverse effects can be increased when Nortriptyline is combined with Chloral hydrate. Approved Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Chloral hydrate. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Chloral hydrate. Approved Ondansetron The risk or severity of adverse effects can be increased when Ondansetron is combined with Chloral hydrate. Approved Opium The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Opium. Approved, Illicit Orphenadrine Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. Approved Osanetant The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Osanetant. Investigational Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Chloral hydrate. Approved Oxethazaine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Oxethazaine. Approved, Investigational Oxprenolol The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Oxprenolol. Approved Oxybuprocaine The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Chloral hydrate. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Chloral hydrate. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Chloral hydrate. Approved, Investigational, Vet Approved Paliperidone The risk or severity of adverse effects can be increased when Paliperidone is combined with Chloral hydrate. Approved Paraldehyde Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Approved, Investigational Paroxetine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Paroxetine. Approved, Investigational Penfluridol The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Penfluridol. Experimental Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Chloral hydrate. Approved, Vet Approved Pentobarbital The risk or severity of adverse effects can be increased when Pentobarbital is combined with Chloral hydrate. Approved, Investigational, Vet Approved Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate. Approved Perazine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Perazine. Approved, Investigational Perospirone The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Perospirone. Approved Perphenazine The risk or severity of adverse effects can be increased when Perphenazine is combined with Chloral hydrate. Approved Pethidine The risk or severity of adverse effects can be increased when Pethidine is combined with Chloral hydrate. Approved Phenazocine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Phenazocine. Experimental Phenibut The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Phenibut. Experimental Phenindione The serum concentration of Phenindione can be increased when it is combined with Chloral hydrate. Approved, Investigational Phenobarbital The risk or severity of adverse effects can be increased when Phenobarbital is combined with Chloral hydrate. Approved, Investigational Phenoperidine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Phenoperidine. Experimental Phenoxyethanol The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Phenoxyethanol. Approved Phenprocoumon The serum concentration of Phenprocoumon can be increased when it is combined with Chloral hydrate. Approved, Investigational Phenytoin The risk or severity of adverse effects can be increased when Phenytoin is combined with Chloral hydrate. Approved, Vet Approved Pimozide The risk or severity of adverse effects can be increased when Pimozide is combined with Chloral hydrate. Approved Pipamperone The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Pipamperone. Approved, Investigational Pipotiazine The risk or severity of adverse effects can be increased when Pipotiazine is combined with Chloral hydrate. Approved, Investigational Piritramide The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Piritramide. Approved, Investigational Pizotifen The risk or severity of adverse effects can be increased when Pizotifen is combined with Chloral hydrate. Approved Pomalidomide The risk or severity of adverse effects can be increased when Pomalidomide is combined with Chloral hydrate. Approved Pramipexole Chloral hydrate may increase the sedative activities of Pramipexole. Approved, Investigational Pramocaine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Pramocaine. Approved Prazepam The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Prazepam. Approved, Illicit Pregabalin The therapeutic efficacy of Chloral hydrate can be increased when used in combination with Pregabalin. Approved, Illicit, Investigational Prilocaine The risk or severity of adverse effects can be increased when Prilocaine is combined with Chloral hydrate. Approved Primidone The risk or severity of adverse effects can be increased when Primidone is combined with Chloral hydrate. Approved, Vet Approved Procaine The risk or severity of adverse effects can be increased when Procaine is combined with Chloral hydrate. Approved, Investigational, Vet Approved Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chloral hydrate. Approved, Vet Approved Promazine The risk or severity of adverse effects can be increased when Promazine is combined with Chloral hydrate. Approved, Vet Approved Promethazine The risk or severity of adverse effects can be increased when Promethazine is combined with Chloral hydrate. Approved, Investigational Propanidid The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Propanidid. Experimental Proparacaine The risk or severity of adverse effects can be increased when Proparacaine is combined with Chloral hydrate. Approved, Vet Approved Propofol The risk or severity of adverse effects can be increased when Propofol is combined with Chloral hydrate. Approved, Investigational, Vet Approved Propoxycaine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Propoxycaine. Approved Protriptyline The risk or severity of adverse effects can be increased when Protriptyline is combined with Chloral hydrate. Approved Proxibarbal The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Proxibarbal. Experimental PSD502 The risk or severity of adverse effects can be increased when Chloral hydrate is combined with PSD502. Investigational Quazepam The risk or severity of adverse effects can be increased when Quazepam is combined with Chloral hydrate. Approved, Illicit Quetiapine The risk or severity of adverse effects can be increased when Quetiapine is combined with Chloral hydrate. Approved Quinisocaine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Quinisocaine. Experimental Raclopride The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Raclopride. Investigational Ramelteon The risk or severity of adverse effects can be increased when Ramelteon is combined with Chloral hydrate. Approved, Investigational Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Chloral hydrate. Approved Remoxipride The risk or severity of adverse effects can be increased when Remoxipride is combined with Chloral hydrate. Approved, Withdrawn Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Chloral hydrate. Approved, Investigational Risperidone The risk or severity of adverse effects can be increased when Risperidone is combined with Chloral hydrate. Approved, Investigational Ritanserin The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ritanserin. Investigational Romifidine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Romifidine. Vet Approved Ropinirole Chloral hydrate may increase the sedative activities of Ropinirole. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Chloral hydrate. Approved Rotigotine Chloral hydrate may increase the sedative activities of Rotigotine. Approved Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Chloral hydrate. Approved Scopolamine The risk or severity of adverse effects can be increased when Scopolamine is combined with Chloral hydrate. Approved, Investigational Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Chloral hydrate. Approved, Vet Approved Sepranolone The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Sepranolone. Investigational Sertindole The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Sertindole. Approved, Investigational, Withdrawn Sertraline The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Sertraline. Approved Sevoflurane The risk or severity of adverse effects can be increased when Sevoflurane is combined with Chloral hydrate. Approved, Vet Approved Sodium oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate. Approved Stiripentol The risk or severity of adverse effects can be increased when Stiripentol is combined with Chloral hydrate. Approved Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Chloral hydrate. Approved, Investigational Sulpiride The risk or severity of adverse effects can be increased when Sulpiride is combined with Chloral hydrate. Approved, Investigational Sultopride The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Sultopride. Experimental Suvorexant Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Approved, Investigational Tandospirone The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tandospirone. Investigational Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate. Approved Tasimelteon The risk or severity of adverse effects can be increased when Tasimelteon is combined with Chloral hydrate. Approved, Investigational Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Chloral hydrate. Approved, Investigational Tetrabenazine The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Chloral hydrate. Approved, Investigational Tetracaine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tetracaine. Approved, Vet Approved Tetrahydropalmatine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tetrahydropalmatine. Investigational Tetrodotoxin The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tetrodotoxin. Investigational Thalidomide Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Approved, Investigational, Withdrawn Thiamylal The risk or severity of adverse effects can be increased when Thiamylal is combined with Chloral hydrate. Approved, Vet Approved Thiopental The risk or severity of adverse effects can be increased when Thiopental is combined with Chloral hydrate. Approved, Vet Approved Thioridazine The risk or severity of adverse effects can be increased when Thioridazine is combined with Chloral hydrate. Approved, Withdrawn Thiothixene The risk or severity of adverse effects can be increased when Thiothixene is combined with Chloral hydrate. Approved Tiagabine The risk or severity of adverse effects can be increased when Tiagabine is combined with Chloral hydrate. Approved, Investigational Tiapride The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tiapride. Approved, Investigational Tiletamine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tiletamine. Vet Approved Tilidine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tilidine. Experimental Tioclomarol The serum concentration of Tioclomarol can be increased when it is combined with Chloral hydrate. Experimental Tizanidine The risk or severity of adverse effects can be increased when Tizanidine is combined with Chloral hydrate. Approved, Investigational Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Chloral hydrate. Approved, Withdrawn Topiramate The risk or severity of adverse effects can be increased when Topiramate is combined with Chloral hydrate. Approved Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Chloral hydrate. Approved, Investigational Tranylcypromine The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chloral hydrate. Approved, Investigational Trazodone The risk or severity of adverse effects can be increased when Trazodone is combined with Chloral hydrate. Approved, Investigational Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Chloral hydrate. Approved, Investigational Tricaine methanesulfonate The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tricaine methanesulfonate. Vet Approved Trichloroethylene The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Trichloroethylene. Approved Trifluoperazine The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chloral hydrate. Approved, Investigational Trifluperidol The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Trifluperidol. Experimental Triflupromazine The risk or severity of adverse effects can be increased when Triflupromazine is combined with Chloral hydrate. Approved, Vet Approved Trimipramine The risk or severity of adverse effects can be increased when Trimipramine is combined with Chloral hydrate. Approved Triprolidine The risk or severity of adverse effects can be increased when Triprolidine is combined with Chloral hydrate. Approved Valproic Acid The risk or severity of adverse effects can be increased when Valproic Acid is combined with Chloral hydrate. Approved, Investigational Venlafaxine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Venlafaxine. Approved Veralipride The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Veralipride. Experimental Vigabatrin The risk or severity of adverse effects can be increased when Vigabatrin is combined with Chloral hydrate. Approved Vinyl ether The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Vinyl ether. Experimental Vortioxetine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Vortioxetine. Approved, Investigational Warfarin The serum concentration of Warfarin can be increased when it is combined with Chloral hydrate. Approved Xenon The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Xenon. Experimental Xylazine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Xylazine. Vet Approved Zaleplon The risk or severity of adverse effects can be increased when Zaleplon is combined with Chloral hydrate. Approved, Illicit, Investigational Ziconotide The risk or severity of adverse effects can be increased when Ziconotide is combined with Chloral hydrate. Approved Zimelidine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Zimelidine. Withdrawn Ziprasidone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Chloral hydrate. Approved Zolazepam The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Zolazepam. Vet Approved Zolpidem Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide The risk or severity of adverse effects can be increased when Zonisamide is combined with Chloral hydrate. Approved, Investigational Zopiclone The risk or severity of adverse effects can be increased when Zopiclone is combined with Chloral hydrate. Approved Zotepine The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Zotepine. Approved, Investigational, Withdrawn Zuclopenthixol The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Chloral hydrate. Approved, Investigational - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0060451
- KEGG Drug
- D00265
- KEGG Compound
- C06899
- PubChem Compound
- 2707
- PubChem Substance
- 46507155
- ChemSpider
- 2606
- ChEBI
- 28142
- ChEMBL
- CHEMBL455917
- PharmGKB
- PA448925
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Chloral_hydrate
- ATC Codes
- N05CC01 — Chloral hydrate
- AHFS Codes
- 28:24.92 — Miscellaneous Anxiolytics Sedatives and Hypnotics
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Not Available Auditory Brainstem Response in Children / Sedation With Chloral Hydrate 1 2 Withdrawn Diagnostic Computerized tomography / Procedural Sedation / Traumatic Brain Injury (TBI) 1 2 Withdrawn Treatment Procedural Sedation 1 3 Completed Diagnostic Children / Electroencephalogram / Epilepsies / Sedation therapy 1 3 Completed Treatment Other Conditions of Brain 1 3 Terminated Treatment Anxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders 1 4 Completed Treatment Heart Diseases 1 4 Completed Treatment Sedation therapy 1 Not Available Completed Not Available Pediatric 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Amerifit Inc.
- Bio Pharm Inc.
- Breckenridge Pharmaceuticals
- Dispensing Solutions
- G & W Labs
- G Pohl Boskamp GmbH and Co. KG
- International Laboratories Inc.
- Letco Medical Inc.
- Major Pharmaceuticals
- Pharmaceutical Association
- Pharmascience Inc.
- Physicians Total Care Inc.
- Qualitest
- United Research Laboratories Inc.
- Vintage Pharmaceuticals Inc.
- Dosage forms
Form Route Strength Ointment Topical Capsule Oral 500 mg Syrup Oral 100 mg - Prices
Unit description Cost Unit Pms-Chloral Hydrate 100 mg/ml Syrup 0.05USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 57 °C PhysProp boiling point (°C) 98 °C PhysProp water solubility 7.93E+005 mg/L (at 25 °C) YALKOWSKY,SH & HE,Y (2003) logP 0.99 HANSCH,C ET AL. (1995) - Predicted Properties
Property Value Source Water Solubility 43.4 mg/mL ALOGPS logP 0.88 ALOGPS logP 0.69 ChemAxon logS -0.58 ALOGPS pKa (Strongest Acidic) 9.51 ChemAxon pKa (Strongest Basic) -5.1 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 40.46 Å2 ChemAxon Rotatable Bond Count 1 ChemAxon Refractivity 29.25 m3·mol-1 ChemAxon Polarizability 11.88 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9591 Blood Brain Barrier + 0.9555 Caco-2 permeable - 0.5795 P-glycoprotein substrate Non-substrate 0.8757 P-glycoprotein inhibitor I Non-inhibitor 0.9923 P-glycoprotein inhibitor II Non-inhibitor 0.9794 Renal organic cation transporter Non-inhibitor 0.9454 CYP450 2C9 substrate Non-substrate 0.7898 CYP450 2D6 substrate Non-substrate 0.9116 CYP450 3A4 substrate Non-substrate 0.7558 CYP450 1A2 substrate Non-inhibitor 0.7969 CYP450 2C9 inhibitor Non-inhibitor 0.8017 CYP450 2D6 inhibitor Non-inhibitor 0.9417 CYP450 2C19 inhibitor Non-inhibitor 0.847 CYP450 3A4 inhibitor Non-inhibitor 0.9446 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9778 Ames test AMES toxic 0.6454 Carcinogenicity Carcinogens 0.616 Biodegradation Not ready biodegradable 0.8453 Rat acute toxicity 2.5068 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9837 hERG inhibition (predictor II) Non-inhibitor 0.9558
Spectra
- Mass Spec (NIST)
- Download (8.88 KB)
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as chlorohydrins. These are alcohols substituted by a chlorine atom at a saturated carbon atom otherwise bearing only hydrogen or hydrocarbyl groups.
- Kingdom
- Organic compounds
- Super Class
- Organohalogen compounds
- Class
- Halohydrins
- Sub Class
- Chlorohydrins
- Direct Parent
- Chlorohydrins
- Alternative Parents
- Carbonyl hydrates / Organochlorides / Hydrocarbon derivatives / Alkyl chlorides
- Substituents
- Chlorohydrin / Carbonyl hydrate / Organic oxygen compound / Hydrocarbon derivative / Organooxygen compound / Organochloride / Alkyl halide / Alkyl chloride / Aliphatic acyclic compound
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- organochlorine compound, aldehyde hydrate, ethanediol (CHEBI:28142) / a small molecule (CPD0-1476)
Drug created on July 31, 2007 07:10 / Updated on April 23, 2018 23:09